Canaccord Growth Conference August confidently live life with ease
|
|
- Raymond Cole
- 5 years ago
- Views:
Transcription
1 Canaccord Growth Conference August 2018 confidently live life with ease
2 Forward-Looking Statements This presentation contains forward-looking statements that are not purely historical regarding Senseonics or its management s intentions, beliefs, expectations and strategies for the future. All forward-looking statements and reasons why results might differ included in this presentation are made as of the date of this presentation, based on information currently available to Senseonics, deal with future events, are subject to various risks and uncertainties, and actual results could differ materially from those anticipated in those forward-looking statements. The risks and uncertainties that may cause actual results to differ materially from Senseonics current expectations are more fully described in Senseonics annual report on Form 10-K for the period ended December 31, 2017, as filed with the Securities and Exchange Commission on March 13, 2018, its most recent quarterly report on Form 10-Q for the period ended June 30, 2018, as filed with the Securities and Exchange Commission on August 8, 2018, and its other reports, each as filed with the Securities and Exchange Commission. Senseonics assumes no obligation to update any such forward-looking statement after the date of this report or to conform these forward-looking statements to actual results.
3 Revenue In Billions High Growth Market $8 Market size in billions CGM fastest growing segment $7 $6 $5 $4 $3 $2 $ $1.2 $1.7 $2.3 $2.2 $4.4 $4.3 $0 CGM 42% YOY Insulin Pumps -4% YOY SMBG* -2% YOY *Based on top 3 companies Close Concerns 2017 Industry Roundup; Management Estimate
4 Factors Impacting CGM Adoption PATIENT AND OFFICE BURDEN DISCRETION VALUE FORM FACTOR AND DISCOMFORT Leading factors are not adequately addressed with traditional CGM offerings
5 27% Discontinue CGM Use Within 1 Year Reason N=262 CGM not working properly / accurate enough 71% Problems with adhesive / insertion 61% Too expensive / not covered by insurance 58% Uncomfortable to wear 41% Using pump / don t want two sites on body 33% CGM too big 28% Type 1 Diabetes (T1D) Exchange Registry (2016)
6 The Goal: Increase Use of CGM Improve glucose control Lower risk of hypoglycemia and take share
7 The Eversense CGM System Sensor Smart Transmitter Mobile App Fully implanted Small size Up to 180 days On-body vibe alerts Removable/Rechargeable Gentle adhesive Real-time readings every 5 mins No extra receiver Trends, alerts w/ predictive alerts the only CGM: with fully implantable sensor sensor that lasts up to 180 days with on-body vibe alerts with a removable transmitter
8 2016 for Eversense CGM (90 Day System) 2017 for Eversense XL CGM (180 Day System) 2018 for Eversense CGM (90 Day System)
9 Europe Distributor Commercialization Contribution Insertions 77% Top 3 countries +60% 1H 18 vs 2017 XL Product 70% Current Users Satisfaction 90% User Rating
10 Europe Commercial Experience Most important features of the Eversense System: New patients Long sensor life Predictive alerts 30% 25% 20% 50% Readings on phone On-body vibe alerts Traditional CGM users New to CGM FGM users Gentle adhesive
11 U.S. - Largest Market DiDirreeccttssaaleess 6.0 M (30%) $18 Billion Insulin Taking Patients 600K Pump $2.3B 350K CGM $1.0B have an unmet need Commercialization Strategy Focused on addressable CGM markets National Diabetes Statistics Report, Kelly Close Industry Roundup April 17, 2017 Drawings are not to scale 1
12 US Launch Execution Approval Distribution Coverage Insertion < 45 Days
13 Ease and Freedom with Eversense Eliminates site maintenance and management of supplies and reordering Eliminates discomfort and skin irritation associated with acrylate adhesives Eliminates the need to carry a separate receiver Freedom Coin
14 Ever Mobile Clinic 1,400 HCP and patients visited since approval Boston New York LA San Diego Washington, DC San Antonio Dallas Atlanta Orlando ADA Hands-on diabetes device training and education to U.S. patients and HCPs in their local areas via a custom-built 18-wheeler mobile training facility.
15 Scalable and Focused HCP Targets Rapid Acting Insulin Rx Volume High Volume CGM CGM-Related Procedure Volume Physician Index = Total Target HCPs: 13,182 Senseonics Primary Targets: 2,600 Initial Core Targets: 300
16 Index Targets and Sales Force Current Field Sales Representatives Clinical Customer Care/Support EOY Target Additional Field Sales Representatives 12
17 Two Paths to Payment DME CPT Code Device Code Description A9276 A9277 Code 0446T 0447T Sensor; invasive (e.g., subcutaneous) disposable, for use with interstitial continuous glucose monitoring system, 1 unit = 1 day CMS 1500 supply Transmitter; external, for use with interstitial continuous glucose monitoring system Implantation Code Description Creation of subcutaneous pocket with insertion of implantable interstitial glucose sensor, including system activation and patient training Removal CMS of implantable 1500 interstitial glucose sensor from subcutaneous pocket via incision Code 0446T 0447T 0448T Implantation Code Description Creation of subcutaneous pocket with insertion of implantable interstitial glucose sensor, including system activation and patient training Removal of implantable interstitial glucose sensor from subcutaneous pocket via incision Removal of implantable interstitial glucose sensor with creation of subcutaneous pocket at different anatomic site and insertion of new implantable sensor, including system activation CMS T Removal of implantable interstitial glucose sensor with creation of subcutaneous pocket at different anatomic site and insertion of new implantable sensor, including system activation
18 # of Covered Lives in Millions Covered Lives Forecast st Published Coverage Policy
19 Eversense Pipeline 365 Day Sensor Life 1x/week calibration 365 Day Sensor Life 1x/week calibration On-Demand: Type 2 FGM Long-term wear with no transmitter Type 1 : Gemini FGM +CGM Flash when desired, CGM for peace of mind Same sensor technology. Expanded opportunities.
20 Senseonics Automated Insulin Delivery IDCL Program 1 2 Eversense CGM / AccuChek Insight / TypeZero algorithm Beta Bionics Program Eversense / ilet Pump and Algorithm incontrol AP System with Eversense Accu Chek Insight Pump ilet Bionic Pancreas System with Eversense *Part of International Diabetes Closed-Loop Trial Pivotal trial in 3 European sites (early 2018)
21 confidently live life with ease
Cowen Investor Conference March confidently live life with ease
Cowen Investor Conference March 2018 confidently live life with ease Forward-Looking Statements This presentation contains certain forward-looking statements that involve risks and uncertainties that could
More informationAnnual Stockholder Meeting May 30, confidently live life with ease
Annual Stockholder Meeting May 30, 2018 confidently live life with ease Forward-Looking Statements This presentation contains certain forward-looking statements that involve risks and uncertainties that
More informationconfidently live life with ease Management Presentation
confidently live life with ease Management Presentation 1 Forward-Looking Statements This presentation contains certain forward-looking statements that involve risks and uncertainties that could cause
More informationJanuary 2017 Investor Presentation. confidently live life with ease
January 2017 Investor Presentation confidently live life with ease Forward-Looking Statements This presentation contains certain forward-looking statements that involve risks and uncertainties that could
More informationPatrick J. Sullivan, President & CEO March 7, 2016 Raymond James 37 th Annual Institutional Conference
Patrick J. Sullivan, President & CEO March 7, 2016 Raymond James 37 th Annual Institutional Conference Forward Looking Statement This presentation may contain forward-looking statements concerning Insulet's
More informationCOMPANY OVERVIEW. July 30, 2018
COMPANY OVERVIEW July 30, 2018 SAFE HARBOR & NON-GAAP FINANCIAL MEASURES Forward Looking Statements Certain statements in this presentation constitute forward-looking statements, including, without limitation,
More informationCOMPANY OVERVIEW. April 26, 2018
COMPANY OVERVIEW April 26, 2018 SAFE HARBOR & NON-GAAP FINANCIAL MEASURES Forward Looking Statements Certain statements in this presentation constitute forward-looking statements, including, without limitation,
More informationDIABETES TECHNOLOGY: WHERE ARE WE NOW AND WHERE ARE WE GOING? Presented by: Tom Brobson
DIABETES TECHNOLOGY: WHERE ARE WE NOW AND WHERE ARE WE GOING? Presented by: Tom Brobson March 3 rd, 2018 Who is this guy? Accelerating Progress 1 Oh that guy! Accelerating Progress 2 STATE OF T1D CARE
More informationCompany Overview February 26, 2019
Company Overview February 26, 2019 SAFE HARBOR Cautionary Note Regarding Forward-Looking Statements Certain statements in this presentation constitute forward-looking statements, including, without limitation,
More informationPatrick J. Sullivan Chief Executive Officer. January 9, 2018 Investor Presentation
Patrick J. Sullivan Chief Executive Officer January 9, 2018 Investor Presentation Forward Looking Statement This presentation may contain forward-looking statements concerning Insulet's expectations, anticipations,
More informationNEW TECHNOLOGIES FOR MANAGING DIABETES ANGELA THOMPSON DNP, FNP-C, BC-ADM, CDE, FAANP
NEW TECHNOLOGIES FOR MANAGING DIABETES ANGELA THOMPSON DNP, FNP-C, BC-ADM, CDE, FAANP No commercial support or sponsorship was received for this project I have nothing to disclose OBJECTIVES Identify at
More informationFlash Glucose Monitoring & Implantable Sensors
Flash Glucose Monitoring & Implantable Sensors Timothy Bailey, MD, FACE, CPI President & CEO, AMCR Institute Clinical Associate Professor, UCSD School of Medicine Disclosures Research Support: Abbott,
More informationCONTINUOUS GLUCOSE MONITORING SOLUTIONS Provided by Roche Diabetes Care
CONTINUOUS GLUCOSE MONITORING SOLUTIONS Provided by Roche Diabetes Care More confidence for your patients 03 GIVING YOU THE CHOICE CGM solutions provided by Roche Diabetes Care Welcome to a world of new
More informationQuick Reference Guide. Sensor Smart Transmitter Mobile App
Quick Reference Guide Sensor Smart Transmitter Mobile App Refer to the Eversense CGM User Guide for more detailed information. For a Spanish version of the User Guide and Quick Reference Guide, please
More informationCOMPANY OVERVIEW. October 12, 2017
COMPANY OVERVIEW October 12, 2017 SAFE HARBOR & NON-GAAP FINANCIAL MEASURES Forward Looking Statements Certain statements in this presentation constitute forward-looking statements, including, without
More informationADA 2018 JUN 25, 2018 ORLANDO, FLORIDA
ADA 2018 JUN 25, 2018 ORLANDO, FLORIDA FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements. They are based on current assumptions and expectations that involve uncertainties
More informationBetter Diagnostics for Life
NASDAQ: NMRD Better Diagnostics for Life Corporate Presentation November 2018 Forward-Looking Statement This presentation includes forward-looking statements that are subject to many risks and uncertainties.
More informationMEDICAL POLICY Continuous Glucose Monitoring Systems and Insulin Pumps
POLICY: PG0177 ORIGINAL EFFECTIVE: 12/01/08 LAST REVIEW: 05/24/18 MEDICAL POLICY Continuous Glucose Monitoring Systems and Insulin Pumps GUIDELINES This policy does not certify benefits or authorization
More informationQUESTION 4. WHAT CLINICAL DATA ARE CURRENTLY AVAILABLE TO SUPPORT EXPANDED CGM COVERAGE BY PAYERS AS PERTAINS TO QUESTIONS 1 AND 3?
500 1 QUESTION 4. WHAT CLINICAL DATA ARE CURRENTLY AVAILABLE TO SUPPORT EXPANDED CGM COVERAGE BY PAYERS AS PERTAINS TO QUESTIONS 1 AND 3? WHAT ADDITIONAL DATA ARE NEEDED? AACE/ACE CGM Consensus Conference:
More informationDiabetes Technology Update. Sarah Konigsberg, MD Diabetes & Endocrine Assoc. April 7, 2018
Diabetes Technology Update Sarah Konigsberg, MD Diabetes & Endocrine Assoc. April 7, 2018 Disclosures None No future technologies are FDA approved Continuous Glucose Monitors Continuous Glucose Monitors
More information37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE
37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE January 2019 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
More informationMEDICAL POLICY Continuous Glucose Monitoring Systems and Insulin Pumps
POLICY: PG0177 ORIGINAL EFFECTIVE: 12/01/08 LAST REVIEW: 07/10/18 MEDICAL POLICY Continuous Glucose Monitoring Systems and Insulin Pumps GUIDELINES This policy does not certify benefits or authorization
More informationSTRATEGIST. MedTech START-UPS TO WATCH. ORTHOPEDICS/SPORTS MEDICINE Orthobiologics at a Crossroads. Wendy Diller. PERSPECTIVE Is Medtech Too White?
SEPTEMBER 14, 2018 Vol. 5, No. 12 MedTech STRATEGIST ORTHOPEDICS/SPORTS MEDICINE Orthobiologics at a Crossroads Wendy Diller DIABETES DEVICES CGM on the Upswing: A Three-Month Implantable Enters the Fray
More information10:20 AM March 5, B 100% 235 u. 124 mg/dl 3 HRS INSULIN ON BOARD:
DEXCOM G5 MOBILE CGM COMPATIBLE B 100% 235 u INSULIN ON BOARD: OPTIONS 10:20 AM March 5, 2017 400 350 300 250 200 150 100 50 1.1 u 1:09 hrs BOLUS 124 mg/dl 3 HRS The pump that gets updated, not outdated.
More information34 th Annual J.P. Morgan Healthcare Conference
JANUARY 2016 34 th Annual J.P. Morgan Healthcare Conference [ 1 ] Forward Looking Statements SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS In addition to historical information, this presentation contains
More informationDexcom Current and Future Technology Innovations. Jorge Valdes Chief Technical Officer
Dexcom Current and Future Technology Innovations 2015 Jorge Valdes Chief Technical Officer G5 App Sensor (Same as G4) Indicated for adults and children down to Age 2 years Tiny insertion needle (26Ga)
More informationCGM and Closing The Loop
CGM and Closing The Loop Dualities Research: Helmsely Charitable Trust, ADA, JDRF, NIDDK Consulting: Abbott Diabetes Care, Roche, Intarcia, Valeritas, Adocia, Big Foot Like With Pumps, We ve Come A Long
More informationAbbott FreeStyle Libre Pro System
Professional CGM Abbott FreeStyle Libre Pro Reader Kit includes: Reader, USB cable, interactive tutorial on USB, and power adapter, user s manual, Quick Start Guide, Quick Reference Guide Kit includes:
More informationLiquid Biopsies. Next Generation Cancer Molecular Diagnostics
Liquid Biopsies Next Generation Cancer Molecular Diagnostics Forward Looking Statements 2 Statements pertaining to future financial and/or operating results, future research, diagnostic tests and technology
More informationINVESTOR DAY JUN 5, 2018 NEW YORK CITY
INVESTOR DAY JUN 5, 2018 NEW YORK CITY HOOMAN HAKAMI EVP AND GROUP PRESIDENT DIABETES GROUP FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements. They are based on current assumptions
More informationMEDICAL POLICY Continuous Glucose Monitoring Systems and Insulin Pumps
POLICY: PG0177 ORIGINAL EFFECTIVE: 12/01/08 LAST REVIEW: 02/13/18 MEDICAL POLICY Continuous Glucose Monitoring Systems and Insulin Pumps GUIDELINES This policy does not certify benefits or authorization
More informationVisionary Private Equity Group is Pleased to Announce its Investment in MEDITE Cancer Diagnostics
Dear VPEG Limited Partner, We hope this investor update finds you well. We're pleased to share with you an important update below on the following: Visionary Private Equity Group is Pleased to Announce
More informationDiagnostics for the early detection and prevention of colon cancer. Fourth-Quarter 2014 Earnings Call February 24, 2015
Diagnostics for the early detection and prevention of colon cancer Fourth-Quarter 2014 Earnings Call February 24, 2015 Safe Harbor Statement Certain statements made in this presentation contain forward-looking
More informationLBL Rev 001. School Guide
School Guide LBL015393 Rev 001 Introduction Welcome to the Dexcom G5 Mobile Continuous Glucose Monitoring (CGM) School Guide. The purpose of this guide is to define CGM, explore the differences between
More informationMichael L. Levitz Chief Financial Officer. November 15, 2017 Investor Presentation
Michael L. Levitz Chief Financial Officer November 15, 2017 Investor Presentation Forward Looking Statement This presentation may contain forward-looking statements concerning Insulet's expectations, anticipations,
More informationFAQs for HCP segment New Instructions for Dexcom G5 Mobile Continuous Glucose Monitoring (CGM) System Non-Adjunctive Indication
FAQs for HCP segment New Instructions for Dexcom G5 Mobile Continuous Glucose Monitoring (CGM) System Non-Adjunctive Indication Q1. The Dexcom G5 Mobile System is the first CGM System to receive FDA approval
More informationAnneli, Martina s daughter In better control with her pump since 2011 MY CHILD HAS TYPE 1 DIABETES
Anneli, Martina s daughter In better control with her pump since 2011 MY CHILD HAS TYPE 1 DIABETES Many parents whose child is diagnosed with Type 1 diabetes wonder: Why is this happening to my child?
More informationBetter Diagnostics for Life
NASDAQ: NMRD Better Diagnostics for Life Corporate Presentation December 2018 Forward-Looking Statement This presentation includes forward-looking statements that are subject to many risks and uncertainties.
More informationNEWS BRIEFING Advances in Technology. moderated by: Irl Hirsch, MD University of Washington Medical Center
NEWS BRIEFING Advances in Technology moderated by: Irl Hirsch, MD University of Washington Medical Center 1 EMBARGO POLICY All recordings are for personal use only and not for rebroadcast online or in
More informationThis is a licensed product of Ken Research and should not be copied
1 TABLE OF CONTENTS 1. The US Diabetes Care Devices Market Introduction 1.1. What is Diabetes and it s Types? 2. The US Diabetes Care Devices Market Size, 2007-2013 3. The US Diabetes Care Devices Market
More informationThe Realities of Technology in Type 1 Diabetes
The Realities of Technology in Type 1 Diabetes May 6, 2017 Rosanna Fiallo-scharer, MD Margaret Frederick, RN Disclosures I have no conflicts of interest to disclose I will discuss some unapproved treatments
More informationPeople with type 1 diabetes and Do It Yourself (DIY) technology solutions ABOUT THIS POSITION STATEMENT
Position Statement People with type 1 diabetes and Do It Yourself (DIY) technology solutions ABOUT THIS POSITION STATEMENT Diabetes Australia believes that people with diabetes should have choice and access
More information1. Continuous Glucose Monitoring
1. Continuous Glucose Monitoring 1. Physiology of interstitial fluid glucose 2. Comparison of CGM and self-monitored blood glucose (SMBG) data 3. Insulin dosing indication in BGM vs. CGM & the FDA 4. Protection
More informationOBALON THERAPEUTICS, INC. (OBLN) The first and only FDA-approved swallowable, gas-filled intragastric balloon for weight loss
OBALON THERAPEUTICS, INC. (OBLN) The first and only FDA-approved swallowable, gas-filled intragastric balloon for weight loss Forward looking statements Except for statements of historical fact, information
More informationPredicts and helps prevent lows with. zero fingersticks NOW FEATURING BASAL-IQ TECHNOLOGY
Predicts and helps prevent lows with * zero fingersticks NOW FEATURING BASAL-IQ TECHNOLOGY Basal-IQ Technology is not a substitute for active self-management of your diabetes. Please see back cover for
More informationToday s Goals 10/6/2017. New Frontiers in Diabetes Technology. Disclosures
New Frontiers in Diabetes Technology Marie E. McDonnell, MD Director, Brigham and Women's Diabetes Program Division of Endocrinology, Diabetes and Hypertension Brigham and Women s Hospital Today s Goals
More informationALLERGAN TO ACQUIRE ZELTIQ FOR $2.47B BEST-IN-CLASS COMPANY IN FAST GROWING BODY CONTOURING SEGMENT
ALLERGAN TO ACQUIRE ZELTIQ FOR $2.47B BEST-IN-CLASS COMPANY IN FAST GROWING BODY CONTOURING SEGMENT ALLERGAN CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS Statements contained in this presentation
More informationLessons From The Type 1 Diabetes Exchange
Lessons From The Type 1 Diabetes Exchange Andrew Ahmann, MD Harold Schnitzer Diabetes Health Center at OHSU Presenter Disclosure Information In compliance with the accrediting board policies, the American
More informationBuilding a Premier Oncology Biotech
Building a Premier Oncology Biotech August 208 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements within
More informationARDELYX REPORTS POSITIVE T3MPO-2 PHASE 3 TRIAL RESULTS IN IBS-C
ARDELYX REPORTS POSITIVE T3MPO-2 PHASE 3 TRIAL RESULTS IN IBS-C OCTOBER 11, 2017 NASDAQ: ARDX FORWARD-LOOKING STATEMENTS To the extent that statements contained in this presentation are not descriptions
More informationCorporate Medical Policy
Corporate Medical Policy Continuous Monitoring of Glucose in the Interstitial Fluid File Name: Origination: Last CAP Review: Next CAP Review: Last Review: continuous_monitoring_of_glucose_in_the_interstitial_fluid
More informationUpdate on Diabetes Technology
Update on Diabetes Technology Andrew Ahmann, MD Professor of Medicine Director, Harold Schnitzer Diabetes Health Center OHSU Objectives: Recognize the growing role of technology in assisting patients and
More informationContinuous Glucose Monitoring
Continuous Glucose Monitoring Information about fully-subsidised continuous glucose monitoring for children and young people with type 1 diabetes Continuous glucose monitoring (CGM) can help in managing
More informationGlobal Remote Cardiac Monitoring Market: Size, Trends & Forecasts ( )
Global Remote Cardiac Monitoring Market: Size, Trends & Forecasts (2016-2020) #910680 $800 55 pages In Stock Report Description Scope of the Report The report entitled Global Remote Cardiac Monitoring
More informationNon-Invasive Glucose Monitoring. Kevin Walls April 12, :30 PM-7:30 PM.
Non-Invasive Glucose Monitoring Kevin Walls April 12, 2018 6:30 PM-7:30 PM. Technology is evolving Technology is evolving at such a rapid rate it s hard to keep up. Imagine living a healthier life without
More informationInstitutional Investor & Analyst Day. September 25, 2018
Institutional Investor & Analyst Day September 25, 2018 Susan Morrison EVP & Chief Administrative Officer SLIDE 2 AGENDA Welcome. Company Vision. Technology Roadmap and Product Innovation. Financial Outlook
More informationCONTINUOUS OR INTERMITTENT GLUCOSE MONITORING IN INTERSTITIAL FLUID
FLUID Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs are dependent
More information1 Dexcom G4 Platinum User Guide May 2012
1 Dexcom G4 Platinum User Guide May 2012 Page 1. Dexcom G4 PLATINUM Continuous Glucose Monitoring System. CE marked for use in 1Dexcom G4 User Guide, May 2012. LBL-011277 Rev04. color display. Dexcom G4
More informationInsulin Pumps and Continuous Glucose Sensors- Embracing Technology. Susan Cavalier, BS, RN, CDE Manager, Diabetes Educator Sanford Diabetes Education
Insulin Pumps and Continuous Glucose Sensors- Embracing Technology Susan Cavalier, BS, RN, CDE Manager, Diabetes Educator Sanford Diabetes Education Diabetes Management Tools in 1974 Insulin pump history
More informationAdvances Towards the Bionic Pancreas.
Advances Towards the Bionic Pancreas. Ron Brazg MD, FACE Rainier Clinical Research Center Renton, WA DISCLOSURES Rainier Clinical Research Center is an independent research facility not directly affiliated
More informationINSPIRED BY GIVE HIM MORE. The MiniMed 670G system is the world s first insulin delivery system that automatically adapts to your child s needs.
INSPIRED BY GIVE HIM MORE. The MiniMed 670G system is the world s first insulin delivery system that automatically adapts to your child s needs. * NOW APPROVED FOR AGES 7 AND UP. Waterproof to a depth
More informationData Management System (DMS) User Guide
Data Management System (DMS) User Guide Eversense and the Eversense logo are trademarks of Senseonics, Incorporated. Other brands and their products are trademarks or registered trademarks of their respective
More informationClinical Chemistry and Clinical Toxicology Devices Panel of the Medical Devices Advisory
This document is scheduled to be published in the Federal Register on 03/01/2018 and available online at https://federalregister.gov/d/2018-04167, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN
More informationTABLE OF CONTENTS. HLC102A - Continuous Glucose Monitoring (CGM): Technologies and Global Markets
TABLE OF CONTENTS CHAPTER 1 INTRODUCTION 1 STUDY GOALS AND OBJECTIVES 1 REASONS FOR DOING THIS STUDY 1 CONTRIBUTIONS TO THE STUDY AND INTENDED AUDIENCE 1 SCOPE AND FORMAT 1 METHODOLOGY AND INFORMATION
More informationInvestor Presentation May 2016
Investor Presentation May 2016 Forward Looking Statements Any statements contained in this presentation that do not describe historical facts may constitute forwardlooking statements as that term is defined
More informationINSPIRED BY GIVE HER MORE. The MiniMed 670G system is the world s first insulin delivery system that automatically adapts to your child s needs.
INSPIRED BY GIVE HER MORE. The MiniMed 670G system is the world s first insulin delivery system that automatically adapts to your child s needs. * NOW APPROVED FOR AGES 7 AND UP. MORE TIME HERE TO USING
More informationOBJECTIVES THE PAST INNOVATIVE TECHNOLOGY & DIABETES DIABETES MIS MANAGEMENT IMPROVEMENTS IN DIABETES MANAGEMENT
OBJECTIVES INNOVATIVE TECHNOLOGY & DIABETES TRISHA PORRETTI, RN, BSN, CDE PWD FOR 25 YEARS Identify important safety features and differences of 3 Continuous Glucose Monitoring (CGM) systems Identify important
More informationDIABETES & ENDOCRINE DIABETES TECHNOLOGY: HOW TO STAY CURRENT WITH ONGOING TECHNOLOGY ADVANCEMENT
DIABETES TECHNOLOGY: HOW TO STAY CURRENT WITH ONGOING TECHNOLOGY ADVANCEMENT Min-Jye Chen, MD Endocrinology Diabetes Management of the School-Aged Child Provided by Texas Children s Hospital Provider #18-267764-A
More informationCorporate Presentation Fourth Quarter 2017
Corporate Presentation Fourth Quarter 2017 November 2017 1 Safe harbor statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
More informationContinuous Glucose Monitoring (CGM)
Continuous Glucose Monitoring (CGM) Date of Origin: 02/2001 Last Review Date: 07/26/2017 Effective Date: 07/26/2017 Dates Reviewed: 04/2004, 04/2005, 03/2006, 11/2006, 12/2007, 03/2008, 09/2008, 04/2009,
More informationApproved by: Integrated Health Quality Management Subcommittee Effective Date: Department of Origin: Integrated Healthcare Services.
Reference #: MC/L008 Page: 1 of 8 PRODUCT APPLICATION: PreferredOne Community Health Plan (PCHP) PreferredOne Administrative Services, Inc. (PAS) ERISA PreferredOne Administrative Services, Inc. (PAS)
More informationUser Guide. A guide for using the Eversense Continuous Glucose Monitoring System. Sensor Smart Transmitter Mobile App
User Guide A guide for using the Eversense Continuous Glucose Monitoring System Sensor Smart Transmitter Mobile App LBL-0202-01-001 Rev 1_Eversense User Guide_mgdL_R6.indd 1 7/22/16 11:38 AM LBL-0202-01-001
More informationGenomic Health. Kim Popovits, Chairman, CEO and President
Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and
More informationArtificial Pancreas Device System (APDS)
Medical Policy Manual Durable Medical Equipment, Policy No. 77 Artificial Pancreas Device System (APDS) Next Review: October 2019 Last Review: October 2018 Effective: November 1, 2018 IMPORTANT REMINDER
More informationTECHNOLOGY & INNOVATION
TECHNOLOGY & INNOVATION Zelko Relic VP RESEARCH & DEVELOPMENT 1 2014 Align Technology, Inc. 1 FORWARD LOOKING STATEMENT During this presentation and corresponding commentary we may make forwardlooking
More informationAquinox Q2 /2015 Conference Call: LEADERSHIP Secondary Endpoint Update - AQX-1125 in BPS/IC. August 6, 2015
Aquinox Q2 /2015 Conference Call: LEADERSHIP Secondary Endpoint Update - AQX-1125 in BPS/IC August 6, 2015 Forward Looking Statements / Safe Harbor This presentation and the accompanying oral commentary
More informationDr Sander Zwart MD, FACP, ECNU Arizona-AACE 2016 Annual Meeting
Dr Sander Zwart MD, FACP, ECNU Arizona-AACE 2016 Annual Meeting Disclaimers None Except products and software discussed are all proprietary, so if I mention a brand product it is because there is no other
More informationEli Lilly and Company
Eli Lilly and Company Strategic Diabetes Alliance with Boehringer Ingelheim January 11 th, 2011 Safe Harbor Provision This presentation contains forward-looking statements that are based on management's
More information- Plans Commercial Launch of three dosing options for Excellagen in pre-filled syringes
Generex Biotechnology Subsidiary Olaregen Therapeutix Inc. Plans Launch of FDA Cleared Excellagen Wound Conforming Gel Matrix with Three Dosage Options - Plans Commercial Launch of three dosing options
More informationDIABETES CARE DEVICES MARKET IN BRAZIL, RUSSIA, INDIA & CHINA (BRIC)
DIABETES CARE DEVICES MARKET IN BRAZIL, RUSSIA, INDIA & CHINA (BRIC) R e p o r t D e s c r i p t i o n T a b l e o f C o n t e n t s L i s t o f T a b l e s S a m p l e T a b l e s R e l a t e d R e p
More informationJDRF RESEARCH UPDATE. Daniel Finan, Ph.D. Research Director
JDRF RESEARCH UPDATE Daniel Finan, Ph.D. Research Director March 10, 2018 PRESENTER Daniel Finan Biomedical engineer B.S. Chemical Engineering University of Colorado, 2003 Ph.D. Chemical Engineering UC
More informationDiagnostics for the early detection and prevention of colon cancer. Leerink Swann Global Health Care Conference February 2015
Diagnostics for the early detection and prevention of colon cancer Leerink Swann Global Health Care Conference February 2015 Safe Harbor Statement Certain statements made in this news release contain forward-looking
More informationCorporate Presentation
Corporate Presentation January 2019 2018 Chembio. All Rights Reserved. # 2019 Chembio. All Rights Reserved. Page 1 Safe Harbor Statement Statements contained herein that are not historical facts are forward-looking
More informationSolutions For The Aging Spine
Solutions For The Aging Spine NASDAQ: ATEC February 2009 www.alphatecspine.com Slide 0 5818 El Camino Real, Carlsbad, CA 92008 www.alphatecspine.com Forward Looking Statements This presentation and our
More informationCommitted to Transforming the Treatment Paradigm for Migraine Prevention
June 14, 2018 Committed to Transforming the Treatment Paradigm for Migraine Prevention September 6, 2018 Forward-Looking Statements This presentation and the accompanying commentary contains certain forward-looking
More informationAdvances in Technology in the Treatment of Diabetes Mellitus 2017 How far have we come-how far are we going? Is there a final frontier?
Advances in Technology in the Treatment of Diabetes Mellitus 2017 How far have we come-how far are we going? Is there a final frontier? Alan B Schorr DO FAAIM FACE www.sugardoc.com abs@sugardoc.com Disclosures
More informationForward Looking Statements and Further Information
JANUARY 2015 [ 1 ] Forward Looking Statements and Further Information SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements. All statements other than
More informationUniversal Biosensors, Inc.
Universal Biosensors, Inc. ARBN 121 559 993 Buchan Three Tickers Presentation 18 th September 2013 1 Important Disclaimer This presentation is intended to provide a general outline only and is not intended
More informationJanuary 30, 2018 Dow Wilson President and Chief Executive Officer
Acquisition of SIRTeX January 30, 2018 Dow Wilson President and Chief Executive Officer This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. Forward-Looking
More information36th Annual J.P. Morgan Healthcare Conference. Kevin Conroy, Chairman and CEO January 9, 2018
36th Annual J.P. Morgan Healthcare Conference Kevin Conroy, Chairman and CEO January 9, 2018 1 Safe harbor statement This presentation contains forward-looking statements within the meaning of Section
More informationTSX-V: VRS OTCQX: VRSEF
Verisante recently announced a breakthrough in the fight against oral and skin cancer with the announcement of a second phase prototype for the Company s Intelligent Multispectral Imaging Camera. Press
More informationContinuous Glucose Monitors for Diabetes Management
Continuous Glucose Monitors for Diabetes Management Ryan Huang, DO PGY II, Sonia Garcia-Jayne, DO PGY II Mandeep Gill, DO PGY I, Justin Leeka, DO, PGY I, Catherine Nguyen OMS IV Family Medicine Residency,
More informationAmylin Pharmaceuticals: Creating Value as a Leader in the Treatment of Diabetes
Amylin Pharmaceuticals: Creating Value as a Leader in the Treatment of Diabetes Daniel M. Bradbury President & Chief Executive Officer JPMorgan Healthcare Conference January 12, 2009 Safe Harbor Statement
More informationUser Guide. A guide for using the Eversense Continuous Glucose Monitoring System. Smart Transmitter. Mobile App
Sensor Smart Transmitter Mobile App User Guide A guide for using the Eversense Continuous Glucose Monitoring System Eversense Trademark Eversense, Eversense Continuous Glucose Monitoring, Eversense CGM,
More informationEndocrine Update Mary T. Korytkowski MD Division of Endocrinology University of Pittsburgh
Endocrine Update 2016 Mary T. Korytkowski MD Division of Endocrinology University of Pittsburgh Disclosure of Financial Relationships Mary Korytkowski MD Honoraria British Medical Journal Diabetes Research
More informationThe Growing Future of Diabetes: Insulin Pump Therapy in Type 1 and 2 Diabetes
The Growing Future of Diabetes: Insulin Pump Therapy in Type 1 and 2 Diabetes Sarah Dombrowski, PharmD, BCACP Pennsylvania Pharmacists Association 10/20/18 1 Objectives At the completion of this activity,
More informationHalozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc. The Next Chapter Begins: Creating Value Through Growth Jefferies 2014 Global Health Care Conference June 2014 Helen Torley, M.B. Ch. B., M.R.C.P. President and Chief Executive
More informationData Management System (DMS) User Guide
Data Management System (DMS) User Guide Eversense and the Eversense logo are trademarks of Senseonics, Incorporated. Other brands and their products are trademarks or registered trademarks of their respective
More informationSenseonics Holdings Inc.
Second Quarter 2016 Earnings Conference Call Tuesday, August, 9, 2016, 4:30 PM Eastern CORPORATE PARTICIPANTS - President and Chief Executive Officer Don Elsey - Chief Financial Officer Mirasol Panlilio
More informationFirst steps for success.
First steps for success. Getting to know continuous glucose monitoring (CGM). The Animas Vibe System is approved for persons age 2 and older. Important Safety Information The Animas Vibe Insulin Pump and
More information